Dr Elena Gubar (Nasonova Research Institute of Rheumatology, Russia) and colleagues analysed disease activity and characteristics of patients with PsA with and without radiographic sacroiliitis in clinical practice.
Patients with PsA (n=385; 213 women and 172 men) according to CASPAR criteria were included. Median age was 45 years; median disease duration was 3.4 years. Patients were divided based on the presence of radiographic sacroiliitis, defined as bilateral grade ≥2 or unilateral grade ≥3:
- with radiographic sacroiliitis: n=214 (55.6%), 108 women and 106 men; and
- without radiographic sacroiliitis: n=171 (44.4%), 105 women and 66 men.
Differences were observed between these 2 groups. HLA-B27 antigen status was positive in 62 patients with radiographic sacroiliitis, compared with 26 patients without radiographic sacroiliitis (OR 1.9). Median tender joint count (TJC) was 9 in patients with radiographic sacroiliitis versus 6 in patients without radiographic sacroiliitis (P=0.02).
Disease activity was measured by Disease Activity Index for Psoriatic Arthritis (DAPSA) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). In patients with radiographic sacroiliitis, DAPSA was higher in patients with versus without radiographic sacroiliitis (28.4 vs 20.0; P<0.05). BASDAI was 1.6 in patients with radiographic sacroiliitis versus 0, respectively (P<0.05). Leeds Enthesitis Index (LEI) was 0 in both patient groups. Dactylitis was present in 71 patients (33.2%) with radiographic sacroiliitis compared with 32 patients (18.7%) without radiographic sacroiliitis (OR 2.2). Furthermore, erosive radiographic arthritis of the feet occurred more often in patients with than without radiographic sacroiliitis (27.1% vs 17.0%; OR 1.8). The affected skin lesion area, evaluated in terms of body surface area (BSA) ≥3% was present in 120 patients with radiographic sacroiliitis and in 141 patients without (OR 0.6). Finally, the median C-reactive protein level in patients with radiographic sacroiliitis was 0.9 mg/dL, whereas in patients without radiographic sacroiliitis it was 0.8 mg/dL (P=0.03).
These results show that many differences are present between patients with and without radiographic sacroiliitis and that patients with radiographic sacroiliitis have more severe disease. Therefore, proper diagnostics of axial involvement are crucial.
- Mease PJ, et al. J Rheumatol. 2018;45:1389–96.
- Gubar E. Association of axial involvement with more severe disease status in psoriatic arthritis patients. Poster P6, 6th World Psoriasis & Psoriatic Arthritis Conference, 30 June–3 July 2021.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Psoriasis registries yield important data about COVID-19 Next Article
Immune checkpoint inhibitors in patients with pre-existing psoriasis »
« Psoriasis registries yield important data about COVID-19 Next Article
Immune checkpoint inhibitors in patients with pre-existing psoriasis »
Table of Contents: WPPAC 2021
Featured articles
Letter from the Editor
Patient Perceptions and Epidemiology
PsoBarrier EU: Large survey evaluating quality of care in Europe
Bridging the gap between patients and access to psoriasis specialists
Psoriasis and PsA in transgender adults on hormone therapy
Disease Progression
Psoriasis: New disease severity classification
Axial involvement is critical in psoriatic arthritis
COVID-19
Psoriasis registries yield important data about COVID-19
COVID-19 affects patients and care
Vaccination feasible in people with psoriatic disease
Low COVID-19 risk for patients with psoriasis on biologic treatment
Pathogenesis and the Gut-Skin Axis
Psoriasis: Disrupted gut-skin axis
Psoriasis associated with increased duodenum inflammation
Whole-exome sequencing to study the underlying pathogenesis of psoriasis
Treatment Guidelines
Pan-European guidelines for the treatment of psoriasis and comorbid conditions
Cardiovascular Comorbidities
Patients with PsA have a higher cardiovascular risk
Potential role of inflammation in cardiovascular comorbidity
New Treatments
Psoriasis: New treatments and current pipeline
Rapid pustule and skin clearance with IL-36 receptor inhibitor spesolimab
Related Articles
December 17, 2020
Promising results with nanobody treatment in psoriasis
November 5, 2022
Novel oral psoriasis drug maintains efficacy over 2 years
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com